Skip to main content
Home
Therapeutic areas
Products
Resources
Events
Contact
English (United Kingdom)
Home
Therapeutic areas
Haematology
Immunology
Nephrology
Specialty Care portfolio
Products
Aspaveli®▼ (pegcetacoplan)
Doptelet® (avatrombopag)
Kineret® (anakinra)
Orfadin® (nitisinone)
Tegsedi® (inotersen)
Waylivra▼ (volanesorsen)
Zynlonta®▼ (loncastuximab tesirine)
Resources
Events
Contact
Prescribing Information
Download file (172 KB)
PP-26169
Oct, 2025
Home
Therapeutic areas
Haematology
Haemophilia
Immune thrombocytopenia (ITP)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Immunology
Interleukin-1 and autoinflammatory diseases
Nephrology
C3G and IC-MPGN
Disease Pathophysiology
Patient Journey – Challenges
Disease Biomarkers
Stay In Touch
Specialty Care portfolio
Products
Aspaveli®▼ (pegcetacoplan)
Doptelet® (avatrombopag)
About ITP
Challenge expectations
Efficacy
Speed of onset and sustainability of response
Consistency of response
Effectiveness following switch from other TPO-RA
Dosing
Safety profile
Guidelines
Resource centre
Kineret® (anakinra)
Home
About Kineret
About IL-1
Still’s disease
CAPS
FMF
Safety
Resources
Orfadin® (nitisinone)
Tegsedi® (inotersen)
Waylivra▼ (volanesorsen)
About FCS
Diagnosing FCS
FCS Pathogenesis
Waylivra
Mode of Action
Efficacy
APPROACH Study - Study Design & Baseline Characteristics
APPROACH Study - Primary Endpoint & Results
Dosing Information
Waylivra Safety Profile
Waylivra Downloadable Resources
Zynlonta®▼ (loncastuximab tesirine)
Home
Efficacy
Post-CAR-T: LOTIS-2 sub-analysis
2-year follow up data
Post-CAR-T: Real-world evidence (RWE)
Dosing and administration
Overall Safety Profile
Non-haematological TEAEs
Haematological & laboratory TEAEs
Special warnings and precautions for use
Myelosuppression, cytopenias management and dose modifications for AEs
Resources
Expert opinion videos
Real World Experience case studies
BSH 2024 highlights
Podcasts
Resources
Events
Contact
Login
Other sites
expand_less